



NEWS RELEASE

FOR IMMEDIATE RELEASE

Contact: Ronald Trahan, APR, President, Ronald Trahan Associates Inc., +1-508-359-4005,x108

Outstanding interim results of STENTYS international clinical study of 600 heart attack patients

Lower rate of adverse events for STENTYS Self-Apposing™ Stent compared to reported results of conventional stents

PRINCETON, N.J., and PARIS, Nov. 8, 2011 — **STENTYS S.A. ([STNT.PA](#))**, a medical technology company commercializing the world's first and only **Self-Apposing™ Stent** to treat **Acute Myocardial Infarction (AMI)**, disclosed today data on 600 patients from its ongoing “**APPOSITION III**” international clinical study who underwent an examination 30 day after treatment of a severe heart attack.

“With only 2.4% of patients experiencing a Major Adverse Cardiac Event (MACE) at 30 days in the latest patient cohort compared to rates of over 5% in published landmark trials with conventional stents, these remarkable preliminary clinical results could challenge the existing gold standard of treating AMI patients with balloon-expandable stents,” said study investigator **Dr. Robert Jan van Geuns, M.D., Ph.D.**, Thorax Center at Erasmus Medical Center, Rotterdam, the Netherlands.

“We believe that these impressive clinical results confirm the Self-Apposing™ technology as *the best* solution for treating heart attack patients, and will contribute to increase its adoption in routine practice,” said **Gonzague Issenmann, CEO and co-founder of STENTYS**.

The STENTYS Self-Apposing™ Stent represents a major breakthrough: it solves the stent sizing dilemma that cardiologists are confronted with when treating heart attack patients with conventional stents. It “fits snugly” into the contour of a blood vessel, and its shape and diameter adapt to the anatomic changes of the coronary arteries during the post-AMI phase, avoiding a major complication of all other conventional stents: **malapposition**.

About STENTYS

Based in Princeton, N.J., and Paris, STENTYS has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by **Jacques Séguin, M.D., Ph.D.**, (also founder of **CoreValve, which was acquired by Medtronic**) and **Gonzague Issenmann**, STENTYS received CE-marking for its flagship products in 2010. Its Self-Apposing™ stent adapt to the anatomic changes of the arteries in the post-infarction phase and thus prevents the malapposition problem associated with conventional stents. STENTYS has commenced marketing activities in several European countries.

#####